Tyme announces interim phase II data for SM-88 in prostate cancer at ASCO GU Symposium

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Tyme Technologies Inc. announced efficacy and safety data from an ongoing phase II trial of SM-88 in patients with non-metastatic, biochemical-recurrent prostate cancer.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

People of African ancestry (Black/African American) have some of the worst cancer incidence and greatest mortality, compared to white and other racial and ethnic populations in the U.S. On average, Black persons are 1.5 times more likely to have cancer and >2X more likely to die from cancer compared to whites. xxx:more

Login